title: Amgen best-seller challenged by generics.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratner
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D059451:Biosimilar Pharmaceuticals; D002738:Chloroquine / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D057186:Comparative Effectiveness Research; D004345:Drug Industry; D016568:Drugs, Generic; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D012460:Sulfasalazine / Q000008:administration & dosage / Q000627:therapeutic use; D013810:Therapeutic Equivalency
chemical_list: D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D016568:Drugs, Generic; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D012460:Sulfasalazine; D002738:Chloroquine; D000068800:Etanercept; D008727:Methotrexate
references.citation: Nat Biotechnol. 2012 Jun 07;30(6):482-4
references.pmid: 22678377
references.citation: N Engl J Med. 2013 Jul 25;369(4):307-18
references.pmid: 23755969